OCGN
Ocugen, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Sell
-29/100
Last price
1.04
■ 0.00 (0.00%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
1.05
Prev close
1.04
Day high
1.12
Day low
1.04
Volume
5.29M
Market cap
$352.67M
P/E (TTM)
—
52W range
0.97 – 2.73
Day trading desk
Gap from prior close
+1.16%
Prior close 1.04
VWAP
1.06
-1.69% from price
Relative volume
1.67×
Unusually busy
Session range
7.69%
1.04 – 1.12
Position in range
0%
Near session low
ATR (14D)
0.06
6.22% of price
Prior day high
1.05
PDH
Prior day low
1.00
PDL
Bid / ask spread
—
Quote not published
Session volume
9.77M
Avg 5.85M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-4.59%
-6.5%
1M
-23.53%
-24.7%
3M
-30.67%
-35.2%
6M
-40.23%
-58.4%
YTD
-22.96%
-37.2%
1Y
-41.24%
-57.7%
3Y
+160.00%
+77.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on OCGN open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-504.99K
Net selling
Buy transactions
1
21.00K shares
Sell transactions
1
525.99K shares
Net transactions
+2
Buys less sells
Sell : buy shares
25.0 : 1
Heavily one-sided
Insider-held shares
5.23M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 9, 26 | MUSUNURI SHANKAR PH.D Chief Executive Officer |
SELL | 525.99K | $589.11K | |
| Jun 15, 26 | JOHNSON-GREENE TREERITA ESSALIMA Chief Financial Officer |
BUY | 21.00K | $25.83K | Direct |
| Apr 1, 26 | ZHANG JUNGE Director |
CONVERSION | 194.13K | $154.30K | Direct |
| Jan 2, 26 | MUSUNURI SHANKAR PH.D Chief Executive Officer |
STOCK | 3.12M | $0 | Direct |
| Jan 2, 26 | RAMACHANDRAN RAMESH Officer |
STOCK | 207.30K | $0 | Direct |
| Nov 26, 24 | FERNANDES PRABHAVATHI Director |
BUY | 10.00K | $9.10K | Direct |
| Nov 22, 24 | CASTILLO KIRSTEN M Director |
BUY | 25.00K | $22.85K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CASTILLO KIRSTEN M |
Director | 75.00K | Purchase |
FERNANDES PRABHAVATHI |
Director | 10.00K | Purchase |
JOHNSON-GREENE TREERITA ESSALIMA |
Chief Financial Officer | 521.35K | Purchase |
MUSUNURI SHANKAR PH.D |
Chief Executive Officer | — | Sale |
RAMACHANDRAN RAMESH |
Officer | 209.10K | Stock Award(Grant) |
ZHANG JUNGE |
Director | 1.36M | Conversion of Exercise of derivative security |
Fundamentals
Market cap$352.67M
Enterprise value$340.61M
Revenue (TTM)$4.58M
Gross profit$-39.18M
EBITDA$-67.17M
Net income$-81.81M
EPS (TTM)$-0.26
Free cash flow$-1.97M
Total cash$100.05M
Total debt$87.99M
Book value / share$-0.05
Shares outstanding339.11M
Float333.78M
Short % of float31.28%
Dividend yield0.00%
Beta (5Y)2.27
Valuation & profitability ratios
Trailing P/E—
Forward P/E-4.11
PEG ratio—
Price / sales—
Price / book—
EV / revenue74.35
EV / EBITDA-5.07
Gross margin0.00%
Operating margin-1105.11%
Profit margin0.00%
Return on equity—
Return on assets-48.44%
Debt / equity—
Current ratio0.80
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $4.41M | $4.05M | $6.04M | $2.49M | — | +8.8% |
| Operating revenue | $4.41M | $4.05M | $6.04M | $2.49M | — | +8.8% |
| Research & development | $39.75M | $32.13M | $39.57M | $56.16M | — | +23.7% |
| Selling, general & admin | $27.58M | $26.69M | $31.99M | $35.40M | — | +3.3% |
| Total operating expense | $67.33M | $58.81M | $71.57M | $91.56M | — | +14.5% |
| Operating income | -$62.92M | -$54.76M | -$65.53M | -$89.07M | — | -14.9% |
| Net interest income | -$4.27M | $563.00K | — | — | -$79.00K | -857.7% |
| Pre-tax income | -$67.85M | -$54.05M | -$63.08M | -$86.80M | — | -25.5% |
| Tax provision | — | — | — | $0 | -$52.00K | — |
| Net income | -$67.85M | -$54.05M | -$63.08M | -$86.80M | — | -25.5% |
| Net income to common | -$67.85M | -$54.05M | -$63.08M | -$86.80M | — | -25.5% |
| Basic EPS | -0.23 | -0.20 | -0.26 | -0.38 | — | -15.0% |
| Diluted EPS | -0.23 | -0.20 | -0.26 | -0.38 | — | -15.0% |
| EBIT | -$62.66M | -$53.37M | -$65.53M | -$89.07M | — | -17.4% |
| EBITDA | -$60.27M | -$51.40M | -$64.83M | -$88.59M | — | -17.3% |
| Basic shares | 300.17M | 271.00M | 244.33M | 214.60M | — | +10.8% |
| Diluted shares | 300.17M | 271.00M | 244.33M | 214.60M | — | +10.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $18.57M | $58.51M | $39.46M | $77.56M | -68.3% |
| Cash & short-term investments | $18.57M | $58.51M | $39.46M | $90.93M | -68.3% |
| Total current assets | $24.34M | $61.68M | $42.97M | $98.49M | -60.5% |
| Property, plant & equipment | $14.39M | $16.55M | $17.29M | $6.05M | -13.1% |
| Total assets | $43.52M | $82.44M | $64.55M | $108.63M | -47.2% |
| Total current liabilities | $23.04M | $21.59M | $17.09M | $28.53M | +6.7% |
| Current debt | $1.25M | $1.33M | — | — | -5.7% |
| Long-term debt | $27.54M | $27.34M | $2.80M | $2.29M | +0.7% |
| Total debt | $33.14M | $32.50M | $6.94M | $6.37M | +2.0% |
| Total liabilities | $55.68M | $52.81M | $23.98M | $34.65M | +5.4% |
| Retained earnings | -$408.07M | -$340.22M | -$286.17M | -$223.09M | -19.9% |
| Shareholder equity | -$12.17M | $29.63M | $40.56M | $73.98M | -141.1% |
| Working capital | $1.30M | $40.09M | $25.88M | $69.96M | -96.8% |
| Net tangible assets | -$12.17M | $29.63M | $40.56M | $73.98M | -141.1% |
| Shares issued | 312.50M | 291.49M | 256.69M | 221.72M | +7.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$67.85M | -$54.05M | -$63.08M | -$86.80M | — | -25.5% |
| Depreciation & amortisation | $2.39M | $1.97M | $704.00K | $480.00K | — | +21.4% |
| Stock-based compensation | $7.71M | $7.43M | $9.22M | $10.54M | — | +3.8% |
| Change in working capital | -$523.00K | $3.67M | -$13.16M | $9.20M | — | -114.3% |
| Operating cash flow | -$56.96M | -$42.14M | -$62.05M | -$60.08M | — | -35.2% |
| Capital expenditure | -$185.00K | -$3.38M | -$10.48M | -$4.46M | — | +94.5% |
| Investing cash flow | -$311.00K | -$3.38M | $3.08M | -$16.97M | — | +90.8% |
| Share buybacks | — | — | — | — | $0 | — |
| Financing cash flow | $17.33M | $64.86M | $20.88M | $59.48M | — | -73.3% |
| Free cash flow | -$57.15M | -$45.53M | -$72.53M | -$64.54M | — | -25.5% |
| End cash position | $18.89M | $58.82M | $39.46M | $77.56M | — | -67.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $1.49M | $1.53M | -$193.00K | $1.75M | $1.37M | -2.9% |
| Operating revenue | $1.49M | $1.53M | -$193.00K | $1.75M | $1.37M | -2.9% |
| Research & development | $10.69M | $11.26M | $10.67M | $11.15M | $8.40M | -5.0% |
| Selling, general & admin | $7.24M | $8.12M | $6.13M | $8.23M | $6.77M | -10.8% |
| Total operating expense | $17.93M | $19.37M | $16.80M | $19.38M | $15.17M | -7.4% |
| Operating income | -$16.44M | -$17.84M | -$17.00M | -$17.63M | -$13.79M | +7.8% |
| Net interest income | -$4.08M | -$1.19M | -$1.19M | -$1.11M | -$1.06M | -243.5% |
| Pre-tax income | -$24.88M | -$19.18M | -$17.71M | -$20.05M | -$14.74M | -29.7% |
| Net income | -$24.88M | -$19.18M | -$17.71M | -$20.05M | -$14.74M | -29.7% |
| Net income to common | -$24.88M | -$19.18M | -$17.71M | -$20.05M | -$14.74M | -29.7% |
| Basic EPS | -0.07 | -0.06 | -0.06 | -0.06 | -0.05 | -16.7% |
| Diluted EPS | -0.07 | -0.06 | -0.06 | -0.06 | -0.05 | -16.7% |
| EBIT | -$20.40M | -$17.86M | -$16.37M | -$18.74M | -$13.45M | -14.2% |
| EBITDA | -$19.82M | -$17.27M | -$16.37M | -$17.79M | -$12.21M | -14.8% |
| Basic shares | 338.68M | 320.42M | 312.34M | 312.32M | 292.07M | +5.7% |
| Diluted shares | 338.68M | 320.42M | 312.34M | 312.32M | 292.07M | +5.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $100.05M | $31.86M | $18.57M | $32.56M | $27.01M | +214.1% |
| Cash & short-term investments | $100.05M | $31.86M | $18.57M | $32.56M | $27.01M | +214.1% |
| Total current assets | $106.72M | $38.55M | $24.34M | $37.64M | $32.88M | +176.8% |
| Property, plant & equipment | $13.35M | $13.83M | $14.39M | $14.95M | $15.45M | -3.5% |
| Total assets | $124.21M | $56.91M | $43.52M | $57.60M | $53.59M | +118.3% |
| Total current liabilities | $133.08M | $20.71M | $23.04M | $20.36M | $17.99M | +542.7% |
| Current debt | $82.38M | $5.00M | $1.25M | — | — | +1,545.9% |
| Long-term debt | $1.73M | $24.19M | $27.54M | $28.40M | $28.02M | -92.9% |
| Total debt | $87.99M | $33.30M | $33.14M | $32.96M | $32.82M | +164.3% |
| Total liabilities | $140.76M | $51.10M | $55.68M | $54.06M | $50.54M | +175.5% |
| Retained earnings | -$452.12M | -$427.24M | -$408.07M | -$390.36M | -$370.31M | -5.8% |
| Shareholder equity | -$16.56M | $5.80M | -$12.17M | $3.53M | $3.05M | -385.2% |
| Working capital | -$26.36M | $17.84M | $1.30M | $17.28M | $14.89M | -247.7% |
| Net tangible assets | -$16.56M | $5.80M | -$12.17M | $3.53M | $3.05M | -385.2% |
| Shares issued | 339.04M | 338.44M | 312.50M | 312.44M | 292.31M | +0.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$24.88M | -$19.18M | -$17.71M | -$20.05M | -$14.74M | -29.7% |
| Depreciation & amortisation | $586.00K | $590.00K | -$397.00K | $950.00K | $1.24M | -0.7% |
| Stock-based compensation | $1.83M | $3.40M | $2.00M | $1.98M | $1.84M | -46.1% |
| Change in working capital | $4.75M | -$6.64M | -$805.00K | $4.77M | $1.98M | +171.5% |
| Operating cash flow | -$12.20M | -$21.79M | -$13.96M | -$12.92M | -$10.73M | +44.0% |
| Capital expenditure | -$21.00K | -$6.00K | -$35.00K | -$91.00K | -$43.00K | -250.0% |
| Investing cash flow | -$21.00K | -$6.00K | -$35.00K | -$86.00K | -$88.00K | -250.0% |
| Financing cash flow | $80.37M | $34.98M | $2.00K | $18.51M | $61.00K | +129.7% |
| Free cash flow | -$12.22M | -$21.80M | -$14.00M | -$13.01M | -$10.77M | +43.9% |
| End cash position | $100.37M | $32.17M | $18.89M | $32.88M | $27.32M | +212.0% |
Options analytics
Put / call volume
0.84
Call-heavy session
Put / call open interest
0.05
Positioning, not flow
Max pain
3.00
+188.5% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
+12.5%
Puts bid over calls
Call volume
226
Contracts, this expiry
Put volume
190
Contracts, this expiry
Heaviest call OI
4.00
240 contracts
Heaviest put OI
0.50
12 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.05 | -0.06 | -16.9% |
| Mar 2026 | -0.05 | -0.06 | -15.4% |
| Dec 2025 | -0.06 | -0.06 | -4.4% |
| Sep 2025 | -0.06 | -0.07 | -21.7% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.05 | 3 | $780.00K | -55.5% |
| Next quarter | -0.06 | 3 | $960.00K | +597.4% |
| Current year | -0.24 | 3 | $4.96M | +12.3% |
| Next year | -0.25 | 3 | $5.50M | +11.0% |
Analyst targets & ownership
Mean target$12.17
High target$22.00
Low target$8.00
Implied upside1069.87%
Analyst count6
ConsensusSTRONG BUY
Strong buy / Buy1 / 5
Hold0
Sell / Strong sell0 / 0
Held by insiders1.54%
Held by institutions43.41%
Institutions holding192
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.03
+1.27% from price
SMA 20
1.03
+1.01% from price
SMA 50
1.21
-14.06% from price
SMA 100
1.28
-19.01% from price
SMA 200
1.49
-30.22% from price
EMA 12
1.04
-0.18% from price
EMA 26
1.10
-5.30% from price
EMA 50
1.18
-11.79% from price
RSI (14)
42.4
Neutral
MACD (12,26,9)
-0.06
Hist 0.01
ATR (14)
0.06
6.22% of price
Realised vol 30D
77.3%
Annualised
Bollinger upper
1.08
20, 2σ
Bollinger lower
0.98
20, 2σ
50 / 200 cross
Death
1.21 vs 1.49
Trend bias
Below 200
-30.22%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.49
More volatile than market
Correlation to SPY
0.25
Largely independent
Realised vol 30D
77.3%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-59.9%
Peak to trough
Max drawdown 5Y
-97.7%
Peak to trough
ATR 14
0.06
6.22% of price
Beta (reported)
2.27
5Y monthly, from filing
Short interest
Shares short
106.06M
Prior 101.77M
Change vs prior
+4.2%
Shorts adding
% of float
31.28%
Heavily shorted
% of shares out
31.28%
Against total outstanding
Days to cover
15.8
Crowded exit
Float
333.78M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 10, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 27, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Mar 25, 26 | Chardan Capital | MAINTAINED | Buy | Buy |
| Mar 25, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 17, 26 | Canaccord Genuity | INITIATED | — | Buy |
| Mar 11, 26 | Oppenheimer | INITIATED | — | Outperform |
| Mar 5, 26 | Chardan Capital | MAINTAINED | Buy | Buy |
| Jan 20, 26 | Chardan Capital | MAINTAINED | Buy | Buy |
| Sep 19, 25 | Chardan Capital | MAINTAINED | Buy | Buy |
| Aug 4, 25 | Chardan Capital | MAINTAINED | Buy | Buy |
| Jun 24, 25 | Chardan Capital | MAINTAINED | Buy | Buy |
| Jun 24, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay dateSep 30, 2019
Last split1:60
Split dateSep 30, 2019
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-10-06
Corporate Changes & Voting Matters
8-K · 2026-09-23
Corporate Changes & Voting Matters
8-K · 2026-09-08
Proxy Statements
DEFA14A · 2026-08-14
Periodic Financial Reports
10-Q · 2026-08-06
Proxy Statements
DEFA14A · 2026-07-30
Proxy Statements
PRE 14A · 2026-07-20
Corporate Changes & Voting Matters
8-K · 2026-07-13
Headlines
Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate
GlobeNewswire · 19h ago
Ocugen to Participate in Upcoming Scientific Conferences
GlobeNewswire · 7d ago
Retinitis Pigmentosa Market Outlook to Strengthen During the Forecast Period (2026-2036) with Growing Focus on Disease-Modifying Therapies | DelveInsight
PR Newswire · 8d ago
Ocugen to Participate in Upcoming October Investor and Industry Conferences
GlobeNewswire · 8d ago
Sector Update: Healthcare Stocks Edge Higher in Afternoon Trading
MT Newswires · 11d ago
Ocugen Gets Provisional Approval for OCU400 in Bahamas
MT Newswires · 12d ago
Ocugen Eyes Global Access For Gene Therapy After Bahamas Boost — First Eye Disorder Patient Could Be Treated Within 90 Days
Stocktwits · 12d ago
Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa
GlobeNewswire · 12d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.